Blueprint Medicines Corporation (BPMC): Price and Financial Metrics
GET POWR RATINGS... FREE!
BPMC POWR Grades
- BPMC scores best on the Value dimension, with a Value rank ahead of 61.51% of US stocks.
- The strongest trend for BPMC is in Quality, which has been heading down over the past 179 days.
- BPMC ranks lowest in Momentum; there it ranks in the 4th percentile.
BPMC Stock Summary
- BPMC's price/sales ratio is 21.88; that's higher than the P/S ratio of 93.42% of US stocks.
- Over the past twelve months, BPMC has reported earnings growth of -308.69%, putting it ahead of merely 6.31% of US stocks in our set.
- As for revenue growth, note that BPMC's revenue has grown -77.31% over the past 12 months; that beats the revenue growth of only 1.54% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Blueprint Medicines Corp, a group of peers worth examining would be XBIT, IDYA, SGMO, DTIL, and XENE.
- BPMC's SEC filings can be seen here. And to visit Blueprint Medicines Corp's official web site, go to www.blueprintmedicines.com.
BPMC Valuation Summary
- In comparison to the median Healthcare stock, BPMC's price/earnings ratio is 55.89% lower, now standing at 16.1.
- Over the past 77 months, BPMC's price/earnings ratio has gone up 26.3.
- BPMC's EV/EBIT ratio has moved up 25.6 over the prior 77 months.
Below are key valuation metrics over time for BPMC.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
BPMC | 2021-08-31 | 6.6 | 4.1 | 16.1 | 14.8 |
BPMC | 2021-08-30 | 6.7 | 4.1 | 16.2 | 15.0 |
BPMC | 2021-08-27 | 6.6 | 4.1 | 16.1 | 14.9 |
BPMC | 2021-08-26 | 6.6 | 4.1 | 16.0 | 14.7 |
BPMC | 2021-08-25 | 6.6 | 4.1 | 16.2 | 14.9 |
BPMC | 2021-08-24 | 6.7 | 4.2 | 16.3 | 15.1 |
BPMC Growth Metrics
- The 2 year net income to common stockholders growth rate now stands at -110.11%.
- Its 2 year revenue growth rate is now at 335%.
- Its 5 year cash and equivalents growth rate is now at 207.83%.

The table below shows BPMC's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2021-12-31 | 180.08 | -298.653 | -644.085 |
2021-09-30 | 107.165 | -309.338 | -411.067 |
2021-06-30 | 828.095 | 408.584 | 340.152 |
2021-03-31 | 809.143 | 370.585 | 325.122 |
2020-12-31 | 793.735 | 387.035 | 313.882 |
2020-09-30 | 811.161 | 366.939 | 333.218 |
BPMC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BPMC has a Quality Grade of C, ranking ahead of 33.2% of graded US stocks.
- BPMC's asset turnover comes in at 0.067 -- ranking 297th of 682 Pharmaceutical Products stocks.
- OTLC, SGEN, and OCGN are the stocks whose asset turnover ratios are most correlated with BPMC.
The table below shows BPMC's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.067 | 0.871 | -0.440 |
2021-06-30 | 0.512 | 0.992 | 0.352 |
2021-03-31 | 0.566 | 0.999 | 0.382 |
2020-12-31 | 0.634 | 0.999 | 0.411 |
2020-09-30 | 0.812 | 1.000 | 0.485 |
2020-06-30 | 0.095 | 0.998 | -0.729 |
BPMC Price Target
For more insight on analysts targets of BPMC, see our BPMC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $119.69 | Average Broker Recommendation | 1.47 (Moderate Buy) |
BPMC Stock Price Chart Interactive Chart >
BPMC Price/Volume Stats
Current price | $55.33 | 52-week high | $117.86 |
Prev. close | $56.91 | 52-week low | $50.96 |
Day low | $53.98 | Volume | 323,860 |
Day high | $56.31 | Avg. volume | 665,435 |
50-day MA | $62.20 | Dividend yield | N/A |
200-day MA | $85.35 | Market Cap | 3.30B |
Blueprint Medicines Corporation (BPMC) Company Bio
Blueprint Medicines Corporation makes kinase drugs to treat patients with genomically defined diseases. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Latest BPMC News From Around the Web
Below are the latest news stories about Blueprint Medicines Corp that investors may wish to consider to help them evaluate BPMC as an investment opportunity.
Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top MarkBlueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down. |
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue EstimatesBlueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Blueprint Medicines Reports Fourth Quarter and Full Year 2021 ResultsBlueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2021. |
Blueprint Medicines to Present at Upcoming Investor ConferencesBlueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences. |
Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseBlueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
BPMC Price Returns
1-mo | -12.89% |
3-mo | -13.10% |
6-mo | N/A |
1-year | -41.63% |
3-year | -34.66% |
5-year | 44.20% |
YTD | -48.34% |
2021 | -4.49% |
2020 | 40.00% |
2019 | 48.60% |
2018 | -28.51% |
2017 | 168.84% |
Continue Researching BPMC
Want to see what other sources are saying about Blueprint Medicines Corp's financials and stock price? Try the links below:Blueprint Medicines Corp (BPMC) Stock Price | Nasdaq
Blueprint Medicines Corp (BPMC) Stock Quote, History and News - Yahoo Finance
Blueprint Medicines Corp (BPMC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...